Summary
Two main classes of oral hypoglycaemic drugs, the sulphonylureas and the biguanides, are currently used in the therapy of type II, non-insulin-dependent diabetes mellitus (NIDDM). The basic pharmacokinetic properties of these agents are discussed with a view to efficient and safe treatment.
Both first- and second-generation sulphonylureas are rapidly absorbed from the gastrointestinal tract. In the plasma compartment, these drugs are strongly bound to serum proteins. All sulphonylureas are metabolised in the liver, and the metabolites and the parent drugs are eliminated mainly in the urine, but also (second-generation derivatives) in the faeces. Rapid- and short-acting sulphonylureas may improve early insulin release and promote better postprandial glucose control. Long-acting derivatives may ensure better control of overnight glycaemia. The elderly are at risk of developing severe sulphonylurea-induced hypoglycaemia, and in this population the agent chosen should have a short or intermediate duration of action and no active metabolites. Caution is needed when prescribing any sulphonylurea in patients receiving drugs known to affect sulphonylurea action, and in those with impaired liver and/or kidney function.
The bioavailability of the biguanides ranges from 40 to 60%. Binding to plasma proteins is absent or very low. Metformin and buformin are not metabolised and are excreted in the urine; phenformin undergoes hepatic hydroxylation and is excreted in both urine and faeces. Metformin is the only agent of this class currently recommended for clinical use. The main indications of metformin treatment are NIDDM associated with obesity and/or hyperlipidaemia, and in combination with sulphonylurea both as primary treatment and when secondary failure occurs with sulphonylurea alone. Lactic acidosis may develop in patients receiving therapy with biguanides, especially in the presence of a preexisting contraindication to their use.
Similar content being viewed by others
References
Benzi L, Trischitta V, Ciccarone AM, Cecchetti P, Brunetti A, et al. Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients. Diabetes 39: 844–849, 1990
Boyd III AE. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 37: 847–850, 1988
Campbell IW. Metformin and the sulfonylureas: comparative risks. Hormone and Metabolic Research 15 (Suppl.): 105–111, 1985
Colwell JA, Lopes-Virella M, Halushka PV. Pathogenesis of atheroslerosis in diabetes mellitus. Diabetes Care 4: 121–131, 1981
Giannarelli R, Marchetti P, Zappella A, Masoni A, di Carlo A, et al. Metformin stimulates insulin release from porcine islets of Langerhans. Diabetologia 31: 493A, 1988
Kolterman OG, Olefsky JM. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care 7 (Suppl. 1): 81–88, 1984
Lebovitz HE. Oral hypoglycemic agents. In Ellenberg & Rifkins (Eds) Diabetes mellitus: theory and practice — 2nd ed., pp. 554–574, 1990
MacKichan JJ. Protein binding drug displacement interactions: fact or fiction? Clinical Pharmacokinetics 16: 65–73, 1989
Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents: an update. Clinical Pharmacokinetics 16: 100–128, 1989
Melander A, Bitzen PO, Faber O, Groop L. Sulfonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 37: 58–72, 1989
Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G. Disposition of metformin (N,N-dimethylbiguanide) in man. Clinical Pharmacology and Therapeutics 24: 683–693, 1978
Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care 10: 118–112, 1987
West KM, Erdreich LJ, Stober JA. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes 29: 501–508, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marchetti, P., Giannarelli, R., di Carlo, A. et al. Pharmacokinetic Optimisation of Oral Hypoglycaemic Therapy. Clin. Pharmacokinet. 21, 308–317 (1991). https://doi.org/10.2165/00003088-199121040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199121040-00006